Last reviewed · How we verify
NCT06379958
Drug-Drug Interaction (DDI) Study of Leramistat in Healthy Adult Subjects
Phase 1 trial testing leramistat 40mg in Pharmacokinetics in 48 participants. Currently enrolling.
30 September 2024
Quick facts
| Lead sponsor | Modern Biosciences Ltd |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 48 |
| Start date | 8 April 2024 |
| Primary completion | 30 September 2024 |
| Estimated completion | 30 September 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- leramistat 40mg — full drug profile →
- Itraconazole 200 mg — full drug profile →
- Phenytoin 100 Mg Oral Capsule — full drug profile →
- Simvastatin 40mg — full drug profile →
- Upadacitinib 15 MG — full drug profile →
Conditions studied
- Pharmacokinetics — all drugs for Pharmacokinetics →
Sponsor
Modern Biosciences Ltd — full company profile →
Who can join
Adults 18 to 55, any sex, with Pharmacokinetics. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A DDI study consisting of 4 parts conducted as an open label, fixed sequence study in healthy adult subjects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06379958
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Pharmacokinetics
Currently open trials in the same condition.
- NCT07583407 — Pharmacokinetics of Kava and Kratom Alone and in Combination · NA · recruiting
- NCT07422285 — Comparing the Extent to Which Two Evolocumab Drug Products Are Made Available in the Body After a Single Subcutaneous Do · Phase 1 · recruiting
- NCT07060209 — Food Effect on PK of DW-1021 (Pelubiprofen 45 mg / Tramadol 45.9 mg) in Healthy Adults · Phase 1 · recruiting
- NCT06859723 — High Potency Cannabis: Acute and Protracted Effects · Phase 1 · recruiting
- NCT06733675 — Safety and PK of Ceftibuten-ledaborbactam Etzadroxil Fixed-dose Combination · Phase 1 · recruiting
Other Modern Biosciences Ltd trials
Trials by the same sponsor.
- NCT05951296 — A Study to Investigate Leramistat in Patients With IPF · Phase 2 · withdrawn
- NCT05460832 — Phase 2b Study of MBS2320 in Participants With Methotrexate-Refractory RA · Phase 2 · completed
- NCT03139136 — Safety, Tolerability and Efficacy of MBS2320 in Patients With Rheumatoid Arthritis · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06379958 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Modern Biosciences Ltd
- Last refreshed: 9 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06379958.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing